Filing Flows › Bionano Genomics (BNGO) › Q1 2026
Bionano Genomics (BNGO) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 13, 2026
Bionano Genomics (BNGO) reported revenue of $6.7M for the first quarter 2026 (Q1 2026), +4% from a year earlier and -16% from the quarter before. Operating margin was -118.1%, net loss $8.3M (124.2% of revenue).
Bionano Genomics, Q1 2026: revenue $6.7M (+4% year over year), operating margin -118.1%, net loss $8.3M, operating cash flow −$5.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $6.7M | -16% | +4% |
| Operating profit | −$7.9M | — | — |
| Net earnings | −$8.3M | — | — |
| Operating cash flow | −$5.7M | — | — |
What changed
Revenue was $6.7M in Q1 2026, up 4% year over year and down 16% from the previous quarter. Consumable Revenue was the largest line at 58% of revenue. Consumable Revenue added $653K year over year (up 20%), 284% of the total change. Software Revenue declined 40%.
Operating costs exceeded revenue by $7.9M, an operating margin of -118.1%. Total costs fell 2% while revenue rose 4%. The fastest-growing cost line was Research & development (+32%). The quarter ended with a net loss of $8.3M, wider than the previous quarter's $7.9M loss.
Operating cash flow was −$5.7M. Non-cash charges added back $2.3M of depreciation and amortization and $670K of share-based compensation. Working capital and other items used $393K.
Questions
What was Bionano Genomics' revenue in the first quarter 2026?
Bionano Genomics (BNGO) reported revenue of $6.7M for the first quarter 2026 (Q1 2026), +4% from a year earlier and -16% from the quarter before.
Was Bionano Genomics profitable in the first quarter 2026?
Operating loss was $7.9M (-118.1% of revenue) and net loss $8.3M.
Source: Bionano Genomics 10-Q on SEC EDGAR.